about
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Developing irreversible inhibitors of the protein kinase cysteinomeSelective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cellsDetermining Cysteines Available for Covalent Inhibition Across the Human Kinome.Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinomaDevelopment of ATP-competitive mTOR inhibitors.Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X ChromosomeStructure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 KinaseDiscovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.Salviachinensines A-F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensisLung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibitionSodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearanceTranscriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistanceDiscovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid LeukemiaDiscovery of ( E)- N1-(3-Fluorophenyl)- N3-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsDiscovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal TumorsClavukoellians A-F, Highly Rearranged Nardosinane Sesquiterpenoids with Antiangiogenic Activity from Clavularia koellikeri
P50
Q27001584-9FD02A4A-A9C8-4BD8-96AE-2D73F5C54294Q27027983-0B25671E-CB8F-4F9E-9232-09F133793E8EQ28486435-32BF864E-C205-4409-8859-721A17A9FCC8Q33859476-C1C031AB-7C8D-4170-830D-D112C2E44549Q35653681-9B5AF19A-C27C-4880-90E0-9BBD171B206AQ35780973-E786B788-A470-4BA6-84FA-B45B9891681AQ37111609-8C19C7B6-AD93-46B0-B6A0-42DF5ABFB20AQ38473974-52F98D48-CF55-487E-9D67-08D3E5D1752BQ38712748-7B008748-554A-48E0-9EFE-96E0F2C554FCQ38718643-2567889F-8046-4327-82A6-D3C4E2A2E7B5Q40064078-448F26EB-1136-4EF8-81FD-C7B17EC12E19Q47731893-5E193934-CF23-4AFC-8FC0-0821C13F08D9Q54113273-BDEE7E47-A8C0-4D3D-9013-B3E06C980FBFQ55447541-FCB5A9B2-47BF-46EC-9F17-C772D470662DQ58104600-7E2EC352-D5E1-4F9C-BA6B-7B335735E583Q64060566-833E1595-C388-4938-885C-6E2D95351D13Q64097844-825810DA-2172-4451-A29E-466BD655967FQ64120283-17E5E9FC-D724-4D4D-809C-E3C86706FE1DQ90631940-D33D6FDA-E703-484D-B895-809A1039B79EQ91695755-B6B90174-3BC6-4499-9C53-95DF6590D176Q92224845-F5E0FC95-1BE7-4094-B460-FF30CD0C311DQ92508576-1977C61A-C6EC-427D-BDEB-F215D81D9825Q93096687-E90C91A8-5B6B-430D-BD9D-4C31B64DE4D9Q93149657-B4B833DC-2202-44DE-9076-25909F84E9E2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Qingsong Liu
@ast
Qingsong Liu
@en
Qingsong Liu
@es
Qingsong Liu
@sl
type
label
Qingsong Liu
@ast
Qingsong Liu
@en
Qingsong Liu
@es
Qingsong Liu
@sl
altLabel
Liu Q S
@en
Liu Qingsong
@en
Q S Liu
@en
Qingsong Liu
@en
prefLabel
Qingsong Liu
@ast
Qingsong Liu
@en
Qingsong Liu
@es
Qingsong Liu
@sl
P106
P31
P496
0000-0002-7829-2547